A phase 2 liver trial where the add-on drug didn't help — and the base drug quietly did
Read the Sunday Brief →

Study wrapper · #875

Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey.

Kjærgaard K, Graabæk T, Thomsen RW, et al. Diabetes, obesity & metabolism. 2026.
MixedCohortMentions: Semaglutide

Editor's note

A cross-sectional pharmacy survey documenting real-world semaglutide dosing patterns and self-reported outcomes for weight management. Weight-loss figures are self-reported and the design is observational, so they describe association and user experience rather than controlled efficacy. The finding that many stay at 1 mg with comparable reported results is a useful, if hypothesis-generating, signal on individualized dosing.

Plain-language abstract

In a Danish pharmacy survey of 767 semaglutide weight-management users, self-reported weight loss rose with longer treatment duration, and many users stayed on the 1 mg dose while reporting effects similar to higher-dose users. About a quarter reported reducing or stopping other medications after starting.